Dyslipidemia, especially hypercholesterolemia and hypoalphalipoproteinemia, is a known risk factor for coronary artery disease. Many pharmacologic agents have been shown to elevate total cholesterol or triglyceride levels or lower HDL cholesterol levels. Our purpose is to review all available cardiac drugs and their influence on lipoprotein metabolism. The major focus will include antianginals, congestive heart failure drugs, antihypertensives, antiarrhythmics, and anticoagulants/antiplatelet agents that are administered chronically. Short-term parenteral drugs will not be discussed.
展开▼
